For sponsors in the United States and European Union, India offers a rare combination of scale, speed, and cost efficiency without compromising data quality. The country is home to roughly 18% of the world’s population, yet only a small share of global clinical trials are conducted there, providing access to a large, undertapped, and often treatment-naïve patient base.
Read our white paper that learn about how Independent analyses report trial costs in India run materially below Western markets, recruitment that is faster than global averages, and how to achieve a regulatory framework with statutory, predictable approval timelines. This paper lays out the evidence-based case for including India in multiregional clinical trial (MRCT) programs.